These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3385635)

  • 1. ICI 169,369 is both a competitive antagonist and an allosteric activator of the arterial 5-hydroxytryptamine2 receptor system.
    Kaumann AJ; Frenken M
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1010-5. PubMed ID: 3385635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine2 receptor system.
    Frenken M; Kaumann AJ
    J Pharmacol Exp Ther; 1989 Aug; 250(2):707-13. PubMed ID: 2760851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-state model for the 5-HT2 receptor: effects of alpha-adrenoceptor ligands.
    Kaumann AJ
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S88-92. PubMed ID: 2459522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors.
    Kaumann AJ; Frenken M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Jan; 328(3):295-300. PubMed ID: 3157064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric properties of the 5-HT2 receptor system of the rat tail artery. Ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulators.
    Frenken M; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):359-66. PubMed ID: 3110629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-hydroxytryptamine antagonistic effects of ICI 169,369, ICI 170,809 and methysergide in human temporal and cerebral arteries.
    Jansen I; Blackburn T; Eriksen K; Edvinsson L
    Pharmacol Toxicol; 1991 Jan; 68(1):8-13. PubMed ID: 2008418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
    Cushing DJ; Cohen ML
    J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
    Ogunbiyi PO; Eyre P
    Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):31-55. PubMed ID: 6328601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ergometrine contracts isolated canine coronary arteries by a serotonergic mechanism: no role for alpha adrenoceptors.
    Brazenor RM; Angus JA
    J Pharmacol Exp Ther; 1981 Aug; 218(2):530-6. PubMed ID: 6114172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric properties of 5-HT2 receptors in tracheal smooth muscle.
    Lemoine H; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jun; 333(2):91-7. PubMed ID: 2944004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery.
    Cushing DJ; Zgombick JM; Nelson DL; Cohen ML
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1560-6. PubMed ID: 8667223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between receptors mediating serotonin (5-HT) contractions in the canine basilar artery to 5-HT1, 5-HT2 and rat stomach fundus 5-HT receptors.
    Cohen ML; Colbert WE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):713-8. PubMed ID: 3712277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.
    Prins NH; Akkermans LM; Lefebvre RA; Schuurkes JA
    Br J Pharmacol; 2001 Nov; 134(6):1351-9. PubMed ID: 11704657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interconversion into a low active state protects vascular 5-HT2-receptors against irreversible antagonism by phenoxybenzamine.
    Frenken M; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 1987 May; 335(5):481-90. PubMed ID: 3614385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR; Joos GF; Pauwels RA
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the contraction to 5-HT in the canine colon longitudinal muscle.
    Prins NH; Briejer MR; Schuurkes JA
    Br J Pharmacol; 1997 Feb; 120(4):714-20. PubMed ID: 9051313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation.
    Bond RA; Ornstein AG; Clarke DE
    J Pharmacol Exp Ther; 1989 May; 249(2):401-10. PubMed ID: 2724131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of specific receptors and calcium mechanisms in serotonergic contractile response of isolated cerebral and peripheral arteries from rats.
    Chang JY; Owman C
    J Pharmacol Exp Ther; 1987 Aug; 242(2):629-36. PubMed ID: 3612555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat.
    Watts SW; Thompson JM
    J Pharmacol Exp Ther; 2004 Apr; 309(1):165-72. PubMed ID: 14724222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.